Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

SeQuent Scientific provides Covid-19 and Business Update

Posted On: 2020-04-08 09:18:45

Sequent Scientific Limited (SSL) today announced a business update to bring investors up to speed on the measures the Company is taking to deal with the COVID-19 crisis and our business outlook at large.

SSL's global management team continues to actively monitor the situation to minimize any impact on its employees, customer deliverables, service and support.

Business Continuity Status

In response to the evolving Covid-19 pandemic, SSL has put in place a Business Continuity Plan (BCP) to deal with the crisis. As part of the plan, factory operations across locations worldwide are working with reduced staff while all nonessential employees have been working remotely. Furthermore, the sales and operations teams continue to work with customers on joint business continuity plans so that we can adapt together as the situation evolves. We have optimized our workloads and made alternate logistics arrangements across all factories to ensure our continued focus and commitment to our clients and target geographies.

As a leadership team we are monitoring both the situation and operations daily to keep things running smoothly.

Industry Impact

Pharmaceuticals and specifically Animal health industry which we cater to, has been categorized as an essential industry across the globe and hence there has been no perceptible impact on the industry. Within the animal health industry, we cater to the production animals' segment, which is not a discretionary spend and hence lock-downs or economic slow-downs have little impact on this business. On the contrary, we do see some positive momentum given that we straddle the generics space which offers better cost dynamics to our customers.

Business Operations

The swift implementation of BCP plan has ensured that we have experienced minimal disruptions to our operations. Our API factories in India did see slight manpower availability disruption at the start of the lockdown, but the situation has since getting better. We expect this situation to continue in the medium term and adequate procedures are in place to continue the BCP for the remainder of the COVID-19 crisis.

Many of our global businesses have shown great resilience during these times. Factories at Spain, Turkey, Germany and Brazil are operating at normal levels while all non-manufacturing related staff are working from home.

We have however put on hold our capacity expansion project at the Germany plant, which was scheduled to be initiated from July 2020 till more clarity emerges. Our ongoing expansion at Vizag have also been suitably moderated to minimise human presence at the site, without impacting the growth prospects.

On the supply chain side, we are fully covered for all key material for both our API and formulation units and the only challenge we face is logistics disruption. We are continuously and pro-actively engaged with the relevant authorities who are helping us to the best of their abilities in keeping the operations ongoing.

Business Outlook

The company has ended FY20 on a strong note, largely achieving both the strategic and operational objectives for the year and continues to move ahead with its organic and inorganic business strategy for its identified core markets of US, EU and Australia. The certainty around Brexit now allows to have a strategic perspective around UK which we are aggressively pursuing. This includes establishing front-end organization either organically or through acquisition as also undertaking aggressive new product filings. We continue to be on track for new product pipeline of 35+ products, which are at various stages of development. The company has recently made significant progress in establishing distribution partnership with a leading global animal health company for India and has initiated CDMO business model for APIs with another animal health major. These recent initiatives shall further add growth engines for the company. The company is also pursuing consolidation of minority interest across its subsidiaries. The management continues to actively identify and pursue new opportunities with new and existing clients to significantly boost volumes and profitability.

We remain confident of our long-term strategy and client relationships.

We appreciate the hard work put in by our teams across various locations to help ensure smooth business operations. We hope and pray for the wellbeing of our employees, clients and shareholders.

Shares of SEQUENT SCIENTIFIC LTD. was last trading in BSE at Rs.79 as compared to the previous close of Rs. 75.35. The total number of shares traded during the day was 29776 in over 524 trades.

The stock hit an intraday high of Rs. 79.5 and intraday low of 72.05. The net turnover during the day was Rs. 2337359.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Amber Enterprises India Ltd Q4 consolidated PAT at Rs. 62.84 crore

Mercury Laboratories Ltd Q4 loss at Rs. 0.35 crore

Moody's downgrades India Infoline Finance Limited to B1 from Ba3, ratings remain under review for downgrade

Mercury Laboratories Ltd Board recommends Dividend of Rs. 2 for FY20

MCX Q4 consolidated net profit up at Rs. 65.50 crore

Lemon Tree Hotels Ltd board approves fund raising proposal

Amara Raja Batteries Ltd reports Q4 FY20 consolidated net profit of Rs. 137.30 crore

Seshasayee Paper and Boards Ltd board recommends dividend of Rs. 4

IDBI Bank Back in Black, registers Net Profit of Rs. 135 crore in Q4 FY 2020 after 13 Quarters

Polycab India Ltd reports Rs. 213.93 crore consolidated PAT in Q4 FY20

KEI Industries Ltd posts consolidated PAT of Rs. 62.03 crore in Q4 FY20

Seshasayee Paper and Boards Ltd Q4 FY20 consolidated PAT at Rs. 48.01 crore

The Great Eastern Shipping Company Ltd board declares interim dividend of Rs. 2.70

Kotak Mahindra Bank allots 6.5 crore shares at Rs. 1145 per share

Affle India Ltd Q4 consolidated PAT up YoY at Rs. 15.28 crore

Advanced Enzyme Technologies Ltd board recommends dividend of Rs. 0.60

RCF's Q4 2019-20 profit after tax rises over 190 % over Q4 2018-19

Eris Lifesciences Ltd board to consider Q4, FY20 results on June 2, 2020

Advanced Enzyme Technologies Ltd Q4 consolidated PAT at Rs. 31.33 crore

Kaveri Seed Company Ltd Q4 FY20 consolidated net profit at Rs. 7.57 crore

Kanpur Plastipack Ltd Board recommends final dividend of Rs. 0.60 for FY20

Techno Electric & Engineering Company Ltd to sell its stake in JKTPL

NLC India Limited raises Rs. 500 crore through Commercial Paper

Kanpur Plastipack Ltd Q4 PAT at Rs. 0.47 crore

CRISIL updates on rating of Jubilant Life Sciences Limited

KRBL Limited board to announce Q4, FY20 results on June 9, 2020

Sagar Cements Ltd reports Rs. 1.29 crore consolidated PAT in Q4 FY20

Procter & Gamble Health Ltd posts Rs. 46.46 crore PAT during the quarter ended March 31, 2020

Customer Service a Priority: Maruti Suzuki announces extension of free service and warranty

Suven Life Sciences Ltd board to consider Q4, FY20 results on June 5, 2020

Everest Industries Ltd Board recommends dividend of Rs. 1 for FY20

ESAF Small Finance Bank Profit Soars 110%

Lemon Tree Hotels Ltd Q4 FY20 loss at Rs. 17.91 crore

IndiGo announces the appointment of Dr. Venkataramani Sumantran as an Independent Director

Sundaram Finance FY20 Net Profit at Rs. 724 crores, revenues up 16% at Rs. 3842 crores

KPTL announces execution of share purchase agreement for divestment of stake in Jhajjar KT Transco Transmission Asset

YES Bank acquires 24.19% in Dish TV India Ltd through invocation of pledged shares

V-Mart reports 16% revenue growth and 61% increase in EBITDA y-o-y in FY20

India Ratings Maintains Union Bank of India on RWE

CRISIL assigns 'CRISIL AAA/Stable' Rating on Rs. 500 crores NonConvertible Debenture (NCD) Programme of M&M

SCI Q4 consolidated PAT at Rs. 111.05 crore

IndiGrid announces execution of share purchase agreement for acquisition of Jhajjar KT Transco Private Limited

The Shipping Corporation of India Limited board recommends final dividend of Rs. 0.75

Sundaram Finance Ltd Board recommends Final Dividend of Rs. 3

Equitas Holdings Ltd Q4 consolidated PAT slides to Rs. 14.59 crore

Metropolis Healthcare Ltd Q4 consolidated PAT drops to Rs. 15.49 crore

VOLTAS Ltd Q4 consolidated PAT up at Rs. 158.66 crore

Andhra Paper Ltd Q4 net profit surges to Rs. 92.92 crore

NCC Limited Q4 consolidated net profit at Rs. 75.82 crore

Shaily Engineering Plastics Ltd Q4 net profit at Rs. 6.95 crore

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019